Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib in Hormone Refractory Prostate Cancer
NCT00093457Phase 2Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- Aug 2004
- Primary completion
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib in prostate cancer (PCa), sponsored by Canadian Cancer Trials Group. Primary endpoint: Prostate-Specific Antigen Response at 2 years. Started Aug 2004; status: completed.
02
Drugs
sorafenib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00093457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00093457.